Dr Lal Pathlabs
Dr Lal PathLabs up 4% on strong September qtr results; more details here
The uptick in Dr Lal PathLabs's share price came on the back of a healthy September quarter of financial year 2025 (Q2FY25) earnings
 "Dr Lal PathLabs up 4% on strong September qtr results; more details here")
Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%
The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India
 "Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%")
Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr
The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row
 "Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr")
Dr Lal PathLabs Q1 results: Net profit up by 29.1%, revenue rises by 11.3%
The company's revenue from operations rose to Rs 602 crore in Q1FY25, an 11.3 per cent Y-o-Y growth from Rs 541 crore reported in Q1FY24
Dr Lal PathLabs Q1FY25 results: Net profit rises 28% to Rs 106 cr
Consolidated net profit rose 28 per cent to Rs 106 cr (around $13 million) for the quarter ended June 30, beating analysts' estimate of Rs 99.27 cr, per LSEG
 "Dr Lal PathLabs Q1FY25 results: Net profit rises 28% to Rs 106 cr")
Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside
5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.
 "Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside")
Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill
Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets
 "Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill")
Dr Lal PathLabs Q4 results: Net profit jumps 49% to Rs 84.5 crore
Eyes expansion into Tier 3 and Tier 4 towns
 "Dr Lal PathLabs Q4 results: Net profit jumps 49% to Rs 84.5 crore")
Dr. Lal PathLabs Q4 results: Net profit rises 49% on healthy testing demand
The company's consolidated net profit jumped 49% year-on-year to Rs 84.5 crore ($10.1 million) in the fourth quarter
Preventive and wellness tests drive growth for diagnostic companies
Covid-19 led to increase in self-testing awareness, particularly about preventive and wellness services
 "Preventive and wellness tests drive growth for diagnostic companies")
Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%
Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities
Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%
Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities
Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%
The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu
 "Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%")
As Covid-19 cases rise in India; should you keep pharma stocks on radar?
Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.
 "As Covid-19 cases rise in India; should you keep pharma stocks on radar?")
Major fire in pathology lab building in Delhi's Rohini; nobody injured
A major fire broke out in a pathology laboratory in north Delhi's Rohini late last night, the fire department said on Monday. No one was reported injured. Officials said that the fire broke out on the third and fourth floor of a building which housed the pathology lab. The fire was reported to the department around 12.45 am. "Total 10 fire engines were rushed to the spot immediately. It took more than two hours to douse the flames completely. The fire was near the lift shaft. No one was injured in the fire," an official of the Delhi Fire Service said. The person said that the police have been informed for further investigation into the matter.
 "Major fire in pathology lab building in Delhi's Rohini; nobody injured")
Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%
Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE
 "Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%")
Dr Lal Pathlabs Q1FY24 result: Profit up 17% YoY; Rs 6 dividend declared
The total income for Q1FY24 came in at Rs 495.1 crore, compared to Rs 459.3 crore year-on-year
 "Dr Lal Pathlabs Q1FY24 result: Profit up 17% YoY; Rs 6 dividend declared")
Dr Lal PathLabs reports decline in profit for quarter ending March
Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from Covid-related testing outpaced growth in its core business
No rerating yet for diagnostic players despite price hikes as margins fall
While discounts have come down, pricing gap still large between incumbents and new players
 "No rerating yet for diagnostic players despite price hikes as margins fall")
No rerating yet for diagnostic players despite price hikes as margins fall
While discounts have come down, pricing gap still large between incumbents and new players
